Analyzing Syros Pharmaceuticals (SYRS) and Kamada (KMDA)

Syros Pharmaceuticals (NASDAQ: SYRS) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Syros Pharmaceuticals and Kamada’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Syros Pharmaceuticals N/A -60.15% -54.25%
Kamada -2.24% -2.94% -2.03%

Valuation and Earnings

This table compares Syros Pharmaceuticals and Kamada’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Syros Pharmaceuticals $1.42 million 296.07 -$48.99 million ($2.13) -7.52
Kamada $87.83 million 2.02 $1.94 million ($0.06) -79.15

Kamada has higher revenue and earnings than Syros Pharmaceuticals. Kamada is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Syros Pharmaceuticals has a beta of -3.79, meaning that its stock price is 479% less volatile than the S&P 500. Comparatively, Kamada has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Syros Pharmaceuticals and Kamada, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syros Pharmaceuticals 0 0 6 0 3.00
Kamada 0 0 2 0 3.00

Syros Pharmaceuticals presently has a consensus target price of $26.37, indicating a potential upside of 64.70%. Kamada has a consensus target price of $8.50, indicating a potential upside of 78.95%. Given Kamada’s higher probable upside, analysts clearly believe Kamada is more favorable than Syros Pharmaceuticals.

Institutional & Insider Ownership

59.6% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 7.3% of Kamada shares are held by institutional investors. 33.6% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Kamada beats Syros Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply